Home

Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)

27.33
-0.29 (-1.05%)

Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing injectable and inhalation products

The company is dedicated to providing high-quality medicines, particularly in the areas of complex generics and niche products, which include both branded and generic formulations. Amphastar's research and development efforts are geared towards addressing unmet medical needs and improving patient outcomes, with a strong emphasis on innovative therapies and cost-effective solutions in various therapeutic areas. Through its commitment to quality and regulatory standards, Amphastar aims to deliver safe and effective pharmaceuticals to healthcare providers and patients around the world.

SummaryNewsPress ReleasesChartHistoricalFAQ
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESS Newswire · March 5, 2025
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024
Via ACCESS Newswire · February 27, 2025
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Via ACCESS Newswire · February 20, 2025
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · January 8, 2025
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · November 26, 2024
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024
Via ACCESSWIRE · November 6, 2024
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024
Via ACCESSWIRE · August 7, 2024
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024
Via ACCESSWIRE · May 8, 2024
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023
Via ACCESSWIRE · February 28, 2024
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · November 13, 2024
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · August 28, 2024
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Via ACCESSWIRE · July 31, 2024
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
Via MarketBeat · June 18, 2024
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
Via ACCESSWIRE · June 4, 2024
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023
Via ACCESSWIRE · November 8, 2023
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · June 3, 2024
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA (albuterol sulfate) Inhalation Aerosol.
Via ACCESSWIRE · May 22, 2024
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · May 9, 2024
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Via ACCESSWIRE · April 30, 2024
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024 at 3:00 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · April 1, 2024
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · March 6, 2024
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Via ACCESSWIRE · February 20, 2024
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · January 2, 2024
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Via ACCESSWIRE · November 20, 2023
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Via ACCESSWIRE · November 9, 2023